Levi & Korsinsky announces it has commenced an investigation of ConforMIS Inc. (“ConforMIS” or the “Company”) (NASDAQGS:CFMS) concerning possible violations of federal securities laws by certain officers and directors.

The investigation concerns whether certain statements made by ConforMIS regarding its business and prospects were false and misleading, resulting in significant investment losses to shareholders. ConforMIS is a medical technology company that uses proprietary technology to develop, manufacture and sell joint replacement implants, individually sized and shaped to each patient. On July 1, 2015, the day of the Company’s IPO, ConforMIS stock opened at $18.00. However, on August 31, 2015, ConforMIS common stock dropped below $16.00, trading as high as $26.93 over that period. The decline was the result of a press release issued by the Company on August 31, 2015 stating that it has begun a recall of specific numbers of patient-specific products in response to three complaints of moisture collecting on those instrumentation. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/conformis-cfms

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.